First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

Autor:	Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner
Zdroj:	University of Southern Denmark Andersen, K T, Hinge, M, Segel, E K, Ormstrup, T, Holdgaard, P, Pallisgaard, N, Kerndrup, G B & Plesner, T 2015, ' First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015 ', 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong, 20/11/2015-21/11/2015 .
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e078e08c8e40f704afeb7eb4d9b85f5a http://findresearcher.sdu.dk/portal/en/publications/firstline-treatment-with-doxorubicin-cyclophosphamide-bortezomib-dexamethasone-and-lenalidomide-acvdl-in-patients-with-multiple-myeloma-icpoep-2015(f9a9529d-ac5d-4147-a388-aa02a6fb5aeb).html Zobrazit plný text záznamu